Press Enter to search · ESC to close

Macro

Bepirovirsen shows 61% functional cure rate in Chinese HBV patients

Bepirovirsen, the world’s first functional cure drug for hepatitis B, achieved up to 61% functional cure rate in Chinese patients, according to data from the global Phase III B-Well study presented by Professor Hou Jinlin at the Asian Hepatology Summit in Singapore on September 4. The drug was approved in Japan in August.

Original source

Share

Related News

TREE NEWS share card
Long-press image above → Save to Photos / Share
Pitch us Feedback